No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Faron Pharmaceuticals said on Monday that updated results from its phase one and two 'BEXMAB' study showed further improvement in the clinical performance of bexmarilimab, strengthening the drug's profile as a treatment for newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).
The AIM-traded firm said the data, presented at the European Society for Medical Oncology (ESMO) Congress 2025 by Dr Mika Kontro of Helsinki University Hospital, confirmed an 85% objective response rate and a 45% complete remission rate among 20 evaluable treatment-nave patients treated with bexmarilimab in combination with azacitidine.
It said 55% of those patients showed full clearance of bone marrow blasts, while those with lower baseline blast counts (
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.